1832 Asset Management L.P. Has $9.48 Million Stock Holdings in HCA Healthcare, Inc. $HCA

1832 Asset Management L.P. lifted its stake in HCA Healthcare, Inc. (NYSE:HCA) by 17.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,733 shares of the company’s stock after acquiring an additional 3,629 shares during the quarter. 1832 Asset Management L.P.’s holdings in HCA Healthcare were worth $9,475,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in HCA. Norges Bank bought a new position in shares of HCA Healthcare in the second quarter valued at $1,152,408,000. Nuveen LLC acquired a new position in shares of HCA Healthcare during the 1st quarter worth about $569,217,000. Price T Rowe Associates Inc. MD lifted its stake in HCA Healthcare by 83.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock valued at $829,104,000 after purchasing an additional 1,091,416 shares during the last quarter. Goldman Sachs Group Inc. increased its position in HCA Healthcare by 49.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock worth $615,583,000 after buying an additional 587,036 shares during the last quarter. Finally, Abdiel Capital Advisors LP bought a new position in shares of HCA Healthcare during the 1st quarter worth approximately $164,835,000. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Price Performance

Shares of NYSE:HCA opened at $487.71 on Friday. The company’s 50 day simple moving average is $458.64 and its 200 day simple moving average is $409.37. The stock has a market capitalization of $111.29 billion, a price-to-earnings ratio of 18.85, a price-to-earnings-growth ratio of 1.44 and a beta of 1.36. HCA Healthcare, Inc. has a 1 year low of $289.98 and a 1 year high of $520.00.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings results on Friday, October 24th. The company reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $1.32. The company had revenue of $19.16 billion for the quarter, compared to analyst estimates of $18.55 billion. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the company posted $4.90 EPS. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. As a group, analysts anticipate that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 29th. Investors of record on Monday, December 15th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $2.88 annualized dividend and a dividend yield of 0.6%. HCA Healthcare’s payout ratio is 11.13%.

Insider Buying and Selling

In other HCA Healthcare news, EVP Michael R. Mcalevey sold 3,892 shares of the business’s stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $473.79, for a total transaction of $1,843,990.68. Following the sale, the executive vice president owned 3,487 shares of the company’s stock, valued at approximately $1,652,105.73. The trade was a 52.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael S. Cuffe sold 3,836 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the transaction, the executive vice president owned 31,503 shares of the company’s stock, valued at $13,194,716.52. The trade was a 10.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of HCA Healthcare in a research report on Monday. TD Cowen upped their target price on HCA Healthcare from $380.00 to $490.00 and gave the company a “buy” rating in a research report on Monday, October 27th. UBS Group boosted their price target on HCA Healthcare from $495.00 to $525.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Wall Street Zen raised HCA Healthcare from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 25th. Finally, Robert W. Baird raised their price target on shares of HCA Healthcare from $380.00 to $423.00 and gave the stock a “neutral” rating in a research report on Thursday, August 14th. Fourteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $474.53.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.